Stifel analyst Derrick Whitfield downgrades Brigham Minerals (NYSE:MNRL) from Buy to Hold and lowers the price target from $31 to $27.
Humanigen’s Lenzilumab Being Studied As A Potential First Treatment In Thirty Years With A Novel Mechanism Of Action For Chronic Myelomonocytic Leukemia (CMML), An Orphan Form Of Leukemia
CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis
Eleven subjects dosed with lenzilumab and with current standard of care, azacitidine
